Literature DB >> 19199980

Fibrates and microvascular complications in diabetes--insight from the FIELD study.

J C Ansquer1, C Foucher, P Aubonnet, K Le Malicot.   

Abstract

Fibrates are widely prescribed lipid-lowering drug in the treatment of dyslipidemia. Their main clinical effects, mediated by peroxisome proliferative activated receptor (PPAR) alpha activation, are a moderate reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, a marked reduction in triglycerides (TG) and an increase in high-density lipoprotein cholesterol (HDL-C), usually dependent of their baseline levels and dyslipidemia type. A beneficial effect on cardiovascular outcomes but also on inflammatory and thrombogenesis pathways as well as antioxidant properties have been evidenced conferring other pleiotropic effects to fibrates. Diabetic retinopathy, nephropathy and neuropathy are the major microvascular complications of Type 2 diabetes mellitus (T2DM) and their presence can accentuate the risk of cardiovascular disease. Hyperglycemia, hypertension, genetic susceptibility among other risk factors play a significant role in the development and progression of these complications. Plasma lipid abnormalities are also involved in the pathogenesis of microvascular diseases suggesting a potential benefit of lipid lowering drugs in their prevention. Clofibrate was the first fibrate in the 60's to show an improvement in the retinal hard exudation in subjects with diabetic retinopathy. Recently, in the Fenofibrate Intervention in Event Lowering in Diabetes (FIELD) study fenofibrate treatment demonstrated a significant 30% reduction in the need for laser therapy in patients with and without known diabetic retinopathy, and more particularly in the first course of laser treatment for both macular edema and proliferative retinopathy. In addition, fenofibrate treatment was associated with less albuminuria progression and reduced risk of non traumatic distal amputations. These results, along with previous evidence of positive effects on microvascular complications, suggest that fibrates, and particularly fenofibrate, offer good opportunity to prevent the most serious complications of diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199980     DOI: 10.2174/138161209787315701

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  26 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

2.  Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.

Authors:  Lucy M Hinder; Claudia Figueroa-Romero; Crystal Pacut; Yu Hong; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2013-10-05       Impact factor: 8.401

Review 3.  Neurological consequences of obesity.

Authors:  Phillipe D O'Brien; Lucy M Hinder; Brian C Callaghan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2017-06       Impact factor: 44.182

4.  Effects of taurine and housing density on renal function in laying hens.

Authors:  Zi-Li Ma; Yang Gao; Hai-Tian Ma; Liu-Hai Zheng; Bin Dai; Jin-Feng Miao; Yuan-Shu Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2016 Dec.       Impact factor: 3.066

5.  Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy.

Authors:  Lucy M Hinder; Andrea M Vincent; John M Hayes; Lisa L McLean; Eva L Feldman
Journal:  Exp Neurol       Date:  2012-10-08       Impact factor: 5.330

Review 6.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

Review 7.  PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

Authors:  Anne Hiukka; Marianna Maranghi; Niina Matikainen; Marja-Riitta Taskinen
Journal:  Nat Rev Endocrinol       Date:  2010-06-22       Impact factor: 43.330

8.  Enteric Glial Dysfunction Evoked by Apolipoprotein E Deficiency Contributes to Delayed Gastric Emptying.

Authors:  Seiichiro Fukuhara; Tatsuhiro Masaoka; Soraya Nishimura; Masaya Nakamura; Juntaro Matsuzaki; Hitoshi Tsugawa; Sawako Miyoshi; Hideki Mori; Satoshi Kawase; Shinsuke Shibata; Hideyuki Okano; Takanori Kanai; Hidekazu Suzuki
Journal:  Dig Dis Sci       Date:  2017-11-02       Impact factor: 3.199

Review 9.  ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.

Authors:  Yan Gong; Zhongjie Fu; Raffael Liegl; Jing Chen; Ann Hellström; Lois Eh Smith
Journal:  Am J Clin Nutr       Date:  2017-05-17       Impact factor: 7.045

Review 10.  Residual microvascular risk in diabetes: unmet needs and future directions.

Authors:  Paola Fioretto; Paul M Dodson; Dan Ziegler; Robert S Rosenson
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.